Skip to content
DraconiticResearch
Search Sources API
190,851 studies31 sourcesUpdated 39 min ago
Peer-reviewedLicence not statedTherapeutic innovation & regulatory science

FDA Accelerated Approval Disclosures on Direct-to-Consumer Prescription Drug Websites: Testing Presence, Prominence, and Wording

  • Helen W. Sullivan1
  • Amie C. O’Donoghue1
  • Mihaela Johnson2
  1. 1US. Food and Drug Administration, Silver Spring, MD USA
  2. 2RTI International, Durham, NC USA
Read full textDOICite

Related

  1. Errors in the Conflict of Interest Disclosures and Methods
    JAMA Network OpenPeer-reviewedCC BY 4.0General medicineCrossref
  2. Errors in Funding/Support Statement and Conflict of Interest Disclosures
    JAMA Network OpenPeer-reviewedCC BY 4.0General medicineCrossref
  3. Lateral-Only Flexible Intramedullary Nailing for Pediatric Tibial Shaft Fractures: An Early Comparative Experience With a Novel Technique to Reduce Symptomatic Implant Prominence
    Alan D. Villegas Meza, Matthew Allen, Brendon C. Mitchell +2
    Journal of the Pediatric Orthopaedic Society of North AmericaPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. FDA Approval Summary: Epcoritamab with Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma
    Rachel Ershler, Xueping Zhou, Keng Hee Peh +12
    Clinical cancer research : an official journal of the American Association for Cancer ResearchPeer-reviewedLicence not statedFull textGeneral medicinePMC
  5. Concerning the harm-benefit ratio of escitalopram for pediatric generalized anxiety disorder. A critical viewpoint on the evidence and approval process
    Martin Plöderl, Mark Horowitz, Florian Naudet +2
    The International Journal of Risk & Safety in MedicinePeer-reviewedCC BY-NC 4.0Full textPharmacology & toxicologyPMC

Cite

BibTeXRIS
BibTeX
@article{sullivan2026accelerated,
  title = {{FDA Accelerated Approval Disclosures on Direct-to-Consumer Prescription Drug Websites: Testing Presence, Prominence, and Wording}},
  author = {Helen W. Sullivan and Amie C. O’Donoghue and Mihaela Johnson},
  journal = {Therapeutic innovation \& regulatory science},
  year = {2026},
  month = jul,
  doi = {10.1007/s43441-026-01018-7},
  url = {https://doi.org/10.1007/s43441-026-01018-7},
}
RIS
TY  - JOUR
TI  - FDA Accelerated Approval Disclosures on Direct-to-Consumer Prescription Drug Websites: Testing Presence, Prominence, and Wording
AU  - Helen W. Sullivan
AU  - Amie C. O’Donoghue
AU  - Mihaela Johnson
PY  - 2026
DA  - 2026/07/15
JO  - Therapeutic innovation & regulatory science
DO  - 10.1007/s43441-026-01018-7
UR  - https://doi.org/10.1007/s43441-026-01018-7
SN  - 2168-4790
SN  - 2168-4804
ER  -